PMC:7696151 / 76189-76360 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2247","span":{"begin":30,"end":33},"obj":"Chemical"},{"id":"2248","span":{"begin":67,"end":77},"obj":"Chemical"},{"id":"2266","span":{"begin":37,"end":43},"obj":"Disease"},{"id":"2267","span":{"begin":97,"end":110},"obj":"Disease"}],"attributes":[{"id":"A2247","pred":"tao:has_database_id","subj":"2247","obj":"MESH:D006886"},{"id":"A2248","pred":"tao:has_database_id","subj":"2248","obj":"MESH:D015251"},{"id":"A2266","pred":"tao:has_database_id","subj":"2266","obj":"MESH:D009369"},{"id":"A2267","pred":"tao:has_database_id","subj":"2267","obj":"MESH:D001943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"essing the contextual role of HCQ in cancer resistance mechanisms. Epirubicin in triple-negative breast cancer therapy often lost efficacy, due to chemoresistance acquirin"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T153","span":{"begin":37,"end":43},"obj":"Phenotype"},{"id":"T154","span":{"begin":97,"end":110},"obj":"Phenotype"}],"attributes":[{"id":"A153","pred":"hp_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A154","pred":"hp_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/HP_0003002"}],"text":"essing the contextual role of HCQ in cancer resistance mechanisms. Epirubicin in triple-negative breast cancer therapy often lost efficacy, due to chemoresistance acquirin"}